GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 19,300 shares, an increase of 14.9% from the July 31st total of 16,800 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average daily volume of 42,500 shares, the days-to-cover ratio is currently 0.5 days.

GT Biopharma Stock Performance

NASDAQ GTBP opened at $2.15 on Monday. GT Biopharma has a one year low of $2.07 and a one year high of $10.66. The firm’s fifty day moving average is $2.56 and its two-hundred day moving average is $3.42.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned 77.02% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 8.15% of the stock is owned by institutional investors.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.